PEYONA Solution (2019)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Peyona 20 mg/ml solution for infusion and oral solution.
Qualitative and quantitative composition
Each ml contains 20 mg caffeine citrate (equivalent to 10 mg caffeine). Each 1 ml ampoule contains 20 mg caffeine citrate (equivalent to 10 mg caffeine) Each 3 ml ampoule contains 60 mg caffeine citrate ...
Pharmaceutical form
Solution for infusion. Oral solution. Clear, colourless, aqueous solution at pH=4.7.
Therapeutic indications
Treatment of primary apnoea of premature newborns.
Posology and method of administration
Treatment with caffeine citrate should be initiated under the supervision of a physician experienced in neonatal intensive care. Treatment should be administered only in a neonatal intensive care unit ...
Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Special warnings and precautions for use
Apnoea Apnoea of prematurity is a diagnosis of exclusion. Other causes of apnoea (e.g. central nervous system disorders, primary lung disease, anaemia, sepsis, metabolic disturbances, cardiovascular abnormalities, ...
Interaction with other medicinal products and other forms of interaction
Inter-conversion between caffeine and theophylline occurs in preterm newborn infants. These active substances should not be used concurrently. Cytochrome P450 1A2 (CYP1A2) is the major enzyme involved ...
Fertility, pregnancy and lactation
Pregnancy Caffeine in animal studies, at high doses, was shown to be embryotoxic and teratogenic. These effects are not relevant with regard to short term administration in the preterm infant population ...
Effects on ability to drive and use machines
Not relevant.
Undesirable effects
Summary of the safety profile The known pharmacology and toxicology of caffeine and other methylxanthines predict the likely adverse reactions to caffeine citrate. Effects described include central nervous ...
Overdose
Following overdose, published plasma caffeine levels have ranged from approximately 50 mg/l to 350 mg/l. Symptoms Signs and symptoms reported in the literature after caffeine overdose in preterm infants ...
Pharmacodynamic properties
Pharmacotherapeutic group: Psychoanaleptics, xanthine derivatives ATC code: N06BC01 Mechanism of action Caffeine is structurally related to the methylxanthines theophylline and theobromine. Most of its ...
Pharmacokinetic properties
Absorption The onset of action of caffeine from caffeine citrate is within minutes of commencement of infusion. After oral administration of 10 mg caffeine base/kg body weight to preterm newborn infants, ...
Preclinical safety data
Non-clinical data revealed no major hazard for humans based on studies of repeated dose toxicity of caffeine. However, at high doses convulsions in rodents were induced. At therapeutic doses some behavioural ...
List of excipients
Citric acid monohydrate Sodium citrate Water for injections
Incompatibilities
This medicinal product must not be mixed or concomitantly administered in the same intravenous line with other medicinal products except those mentioned in section 6.6.
Shelf life
Shelf life: 3 years. After opening the ampoule, the medicinal product should be used immediately. Chemical and physical compatibility of the diluted solution has been demonstrated for 24 hours at 25°C ...
Special precautions for storage
This medicinal product does not require any special storage condition. For storage conditions of the diluted medicinal product see section 6.3.
Nature and contents of container
Type I clear glass 1 ml ampoule. Type I clear glass 3 ml ampoule. Pack size of 10 ampoules.
Special precautions for disposal and other handling
Aseptic technique must be strictly observed throughout handling of the medicinal product since no preservative is present. Peyona should be inspected visually for particulate matter and discoloration prior ...
Marketing authorization holder
CHIESI FARMACEUTICI SpA, Via Palermo 26/A, 43122, Parma, ITALY
Marketing authorization number(s)
EU/1/09/528/002 1ml ampoules EU/1/09/528/001 3ml ampoules
Date of first authorization / renewal of the authorization
Date of first authorisation: 02/07/2009 Date of latest renewal: 03/03/2014
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
